Abstract
Abstract
Background
Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B. Recent evidence has shown that the synergistic use of flucytosine improves efficacy and reduces toxicity, however affordability and availability has hampered access to flucytosine in many countries. This study investigated the evidence and cost implications of introducing flucytosine as induction therapy for cryptococcal meningitis in HIV-infected adults in South Africa.
Methods
A decision analytic cost-effectiveness and cost impact model was developed based on survival estimates from the ACTA trial and local costs for flucytosine as induction therapy in HIV-infected adults with cryptococcal meningitis in a public sector setting in South Africa. The model considered five treatment arms: (a) standard of care; 2-week course amphotericin B/fluconazole (2wk AmBd/Flu), (b) 2-week course amphotericin B/flucytosine (2wk AmBd/5FC), (c) short course; 1-week course amphotericin B/flucytosine (1wk AmBd/5FC) (d) oral course; 2-week oral fluconazole/flucytosine (oral) and e) 1-week course amphotericin B/fluconazole (1wk AmBd/Flu). A sensitivity analysis was conducted on key variables.
Results
The highest total treatment costs are in the 2-week AmBd/5FC arm followed by the 2-week oral regimen, the 1-week AmBd/5FC, then standard of care with the lowest cost in the 1-week AmBd/Flu arm. Compared to the lowest cost option the 1-week flucytosine course is most cost-effective at USD119/QALY. The cost impact analysis shows that the 1-week flucytosine course has an incremental cost of just over USD293 per patient per year compared to what is currently spent on standard of care. Sensitivity analyses suggest that the model is most sensitive to life expectancy and hospital costs, particularly infusion costs and length of stay.
Conclusions
The addition of flucytosine as induction therapy for the treatment of cryptococcal meningitis in patients infected with HIV is cost-effective when it is used as a 1-week AmBd/5FC regimen. Savings could be achieved with early discharge of patients as well as a reduction in the price of flucytosine.
Funder
United States Agency for International Development
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–81. DOI. https://doi.org/10.1016/S1473-3099(17)30243-8.
2. GERMS-SA Annual Report 2017. Accessed 02 February 2019. Available from: http://www.nicd.ac.za/index.php/publications/germs-annual-reports/.
3. Southern African HIV Clinicians Society, Govender N, Meintjes G, Bicanic T, Dawood H, Harrison T, Jarvis KA, et al. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons. S Afr J HIV Med. 2013;14(2):76–86, Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. https://doi.org/10.4102/sajhivmed.v14i2.82.
4. Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect Dis. 2019;19(4):e143–7. https://doi.org/10.1016/S1473-3099(18)30493-6.
5. WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2018. http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/ (accessed May 2019).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献